icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Barcelona, Spain
13-17 April 2016
Back grey_arrow_rt.gif
 
 
 
Arbutus to Present Preclinical HBV Data at EASL 2016
 
 
  VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 30, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the European Association for the Study of the Liver (EASL) selection committee has accepted an abstract for presentation at the EASL 2016 annual meeting to be held April 13 - 17, 2016, in Barcelona, Spain.
 
"We are pleased to present data on our core protein/capsid assembly inhibitor program, which supports our strategy of attacking HBV through multiple different mechanisms of action," said Dr. Mark J. Murray, Arbutus' President and CEO. "Our lead HBV product candidate, ARB-1467, is in an ongoing Phase II study in chronically infected HBV patients. In addition, we are advancing our other HBV programs to support initiation of clinical combination studies in 2017."
 
Poster Presentation
 
Title: "In Vitro and In Vivo Antiviral Activities of AB-423 a Potent Small
Molecule Inhibitor of Hepatitis B Virus Capsid Assembly"
Date: Thursday, April 14, 2016
Abstract Number: THU-198
 
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.  Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit http://arbutusbio.com/.
 
Contact Information
 
Investors

 
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200
Email: acutler@arbutusbio.com
Helia Baradarani
Manager, Investor Relations
Phone: 604.419.3200
Email: hbaradarani@arbutusbio.com
 
Media
 
Please direct all media inquiries to: media@arbutusbio.com